Akcea Therapeutics (NASDAQ:AKCA) is set to post its quarterly earnings results after the market closes on Tuesday, August 6th. Analysts expect Akcea Therapeutics to post earnings of ($0.38) per share for the quarter.
Akcea Therapeutics (NASDAQ:AKCA) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.24 by ($0.90). Akcea Therapeutics had a negative return on equity of 54.63% and a negative net margin of 79.88%. The company had revenue of $163.82 million during the quarter, compared to analyst estimates of $171.40 million. During the same period last year, the firm earned ($0.44) earnings per share. The business’s revenue was up 857.5% compared to the same quarter last year. On average, analysts expect Akcea Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ AKCA traded up $0.57 during trading on Tuesday, reaching $22.35. The company had a trading volume of 3,592 shares, compared to its average volume of 187,974. Akcea Therapeutics has a twelve month low of $19.67 and a twelve month high of $40.75. The stock has a market capitalization of $2.05 billion, a PE ratio of -8.13 and a beta of 1.57. The business’s 50-day simple moving average is $22.97. The company has a quick ratio of 6.61, a current ratio of 6.61 and a debt-to-equity ratio of 0.04.
Several equities analysts recently commented on AKCA shares. ValuEngine upgraded Xylem from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Zacks Investment Research lowered General Finance from a “buy” rating to a “hold” rating in a research note on Monday, July 15th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Akcea Therapeutics has a consensus rating of “Hold” and a consensus target price of $39.40.
In related news, President Sarah Boyce sold 1,819 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $23.52, for a total value of $42,782.88. Following the completion of the transaction, the president now directly owns 19,888 shares in the company, valued at $467,765.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.10% of the company’s stock.
About Akcea Therapeutics
Akcea Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy.
See Also: What is a death cross?
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.